Bacillus coagulans IDCC 1201 and sleep
Proportion and duration of sleep in a study of IDCC 1201 in adults with sleep complaints.
Key points
- In adults with sleep complaints, after four weeks of IDCC 1201 the proportion of time asleep during an overnight assessment increased by 13.71 percentage points, while it changed little with placebo. This is a result of measurements before and after the course. [1] See the evidence 1
- Sleep duration during the same assessments increased by an average of approximately 50 minutes with IDCC 1201 and changed little with placebo. This is not an average gain for every night at home. [1] See the evidence 1
Practical guide
Check the findings and their applicability to your situation.
IDCC 1201 was studied in adults with sleep complaints using an overnight assessment.
Key points
Why these conclusions
Sleep measurements
Adults with sleep complaints took 5 billion CFU of IDCC 1201 one hour before bedtime or placebo for four weeks. The proportion of sleep during the assessment increased from 75.75% to 89.46% with the supplement and changed from 85.08% to 84.93% with placebo; certainty is low — 2 out of 4. [1]
Sleep time during the assessment increased by 49.56 minutes with the supplement and decreased by 0.50 minutes with placebo. Before the course the supplement group slept less; measurements were taken before and after the course, and certainty is low — 2 out of 4. [1]
The proportion of time asleep during the overnight assessment increased from 75.75% to 89.46% on the supplement and changed from 85.08% to 84.93% on placebo: +13.71 versus −0.15 percentage points. The difference remained after adjustment for baseline measures (p=0.015).
| Parameter | Data |
|---|---|
| Result | The proportion of time asleep during the overnight assessment increased from 75.75% to 89.46% on the supplement and changed from 85.08% to 84.93% on placebo: +13.71 versus −0.15 percentage points. The difference remained after adjustment for baseline measures (p=0.015). |
| Participants | 80 adults aged 19–65 with sleep complaints: PSQI sleep quality score ≥5 and ISI insomnia score 8–21. A total of 78 completed the study, 39 per group. Severe insomnia and diagnosed sleep apnea were excluded. |
| Form | IDCC 1201: capsule containing live bacteria |
| Dose | 5 billion CFU in one capsule daily, one hour before bedtime |
| Dose basis | 5 billion CFU in one capsule daily, one hour before bedtime |
| Comparison | Matching placebo capsule with maltodextrin |
| Duration | 4 weeks |
| Certainty | 2/4: One four-week study. Before taking the supplement, the probiotic group slept worse than the placebo group. Objective sleep was assessed during overnight examinations before and after the course; this is not the average change for each night at home. For the proportion of sleep, the advantage remained after adjustment for baseline differences. |
| Body of evidence | 1 publication described |
| Sources | [1] |
Sleep time during the overnight assessment increased by an average of 49.56 minutes on the supplement and decreased by 0.50 minutes on placebo (p=0.002). Before the course the supplement group slept an average of 272.88 minutes and the placebo group 306.25 minutes.
| Parameter | Data |
|---|---|
| Result | Sleep time during the overnight assessment increased by an average of 49.56 minutes on the supplement and decreased by 0.50 minutes on placebo (p=0.002). Before the course the supplement group slept an average of 272.88 minutes and the placebo group 306.25 minutes. |
| Participants | 80 adults aged 19–65 with sleep complaints: PSQI sleep quality score ≥5 and ISI insomnia score 8–21. A total of 78 completed the study, 39 per group. Severe insomnia and diagnosed sleep apnea were excluded. |
| Form | IDCC 1201: capsule containing live bacteria |
| Dose | 5 billion CFU in one capsule daily, one hour before bedtime |
| Dose basis | 5 billion CFU in one capsule daily, one hour before bedtime |
| Comparison | Matching placebo capsule with maltodextrin |
| Duration | 4 weeks |
| Certainty | 2/4: One four-week study. Before taking the supplement, the probiotic group slept worse than the placebo group. Sleep duration was an additional outcome. It was measured during overnight assessments before and after the course; this is not the average change for each night at home. |
| Body of evidence | 1 publication described |
| Sources | [1] |
Information from the source
Gas and digestive discomfort are possible. In the MTCC 5856 study, one participant experienced short-lived heartburn and nausea. In the sports study, one participant in the supplement group withdrew because of vomiting and loose stools; there was also a withdrawal in the placebo group because of vomiting and discomfort. This alone does not prove that the probiotic was the cause. In cases of severe illness or weakened immunity, discuss the choice of a live probiotic with a doctor: infections associated with probiotic microorganisms have been described in vulnerable people. Preterm infants are a particularly vulnerable group. These risks concern probiotics in general; their frequency for a specific strain is not assessed here. The sports study used whey milk protein; the powder contained lactose, and lactose was added instead of the probiotic in the comparison group. If you have a milk protein allergy or lactose intolerance, check the entire product composition. [2] [3] [4]
Information from the source
| Name | Description | Sources |
|---|---|---|
| Strain and number of live bacteria | Unique IS2, MTCC 5856, IDCC 1201, BC99 and SANK70258 have different studies. When choosing, the full strain name, CFU count through the end of shelf life and storage conditions on the label are important. A higher CFU count alone does not mean a greater effect. | [5] [6] [4] [1] [7] [2] [8] [3] |
| Live and nonliving cells | Inactivated cells contain no live bacteria. Their cell count cannot be considered a dose of live probiotic, nor can results from trials of live strains be transferred to them. | [9] [3] |
| Sports option | Unique IS2 was studied together with 20 g of whey powder daily and resistance training. The available description does not specify whether the probiotic itself was in a capsule or powder. | [2] |
Sources
- Efficacy and Safety of Bacillus coagulans IDCC 1201 for Sleep Improvement in Adults with Sleep Disturbance: A Randomized, Double-Blind, Placebo-Controlled Polysomnographic Study. https://pubmed.ncbi.nlm.nih.gov/42196985/
- The effect of Bacillus coagulans Unique IS-2 supplementation on plasma amino acid levels and muscle strength in resistance trained males consuming whey protein: a double-blind, placebo-controlled study. https://pubmed.ncbi.nlm.nih.gov/35249118/
- Probiotics — Health Professional Fact Sheet (NIH ODS). https://ods.od.nih.gov/factsheets/Probiotics-HealthProfessional/
- The effects of Bacillus coagulans MTCC 5856 on functional gas and bloating in adults: A randomized, double-blind, placebo-controlled study. https://pubmed.ncbi.nlm.nih.gov/36862903/
- Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults. https://pubmed.ncbi.nlm.nih.gov/31434935/
- Bacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial. https://pubmed.ncbi.nlm.nih.gov/40456531/
- Effect of Bacillus coagulans BC99 supplementation on body weight and gut microbiota in overweight and obese individual: a randomized, double-blind, placebo-controlled study. https://pubmed.ncbi.nlm.nih.gov/40416368/
- Improvement of skin condition and intestinal microbiota via Heyndrickxia coagulans SANK70258 intake: A placebo-controlled, randomized, double-blind, parallel-group comparative study. https://pubmed.ncbi.nlm.nih.gov/39127017/
- GRAS Notice 670: Inactivated Bacillus coagulans GBI-30, 6086. https://www.fda.gov/media/100803/download
Methodology: Subpages evidence-led supplement pipeline v1